The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice
EMA601 is a conceptually novel and promising anti-platelet agent to efficiently prevent or treat arterial thrombosis and thrombo-inflammatory pathologies in humans at risk.
Authors
- Sarah Beck (ORCID: https://orcid.org/0000-0002-7102-8241)
- Bernhard Nieswandt (ORCID: https://orcid.org/0000-0003-1454-7413)
- Ivan Talucci (ORCID: https://orcid.org/0000-0001-5617-8869)
- Stefano Navarro (ORCID: https://orcid.org/0000-0002-1112-8400)
- Hans Michael Maric (ORCID: https://orcid.org/0000-0002-2719-4752)
- Vanessa Göb (ORCID: https://orcid.org/0000-0003-0813-8680)
- Guido Stoll (ORCID: https://orcid.org/0000-0003-2474-5165)
- Valerie Orth
- David Stegner (ORCID: https://orcid.org/0000-0003-1059-9865)
- Stefanie Hartmann
Institutions
- University of Würzburg (DE)
- Systems Analytics (United States) (US)
- Universitätsklinikum Würzburg (DE)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1093/eurheartj/ehae482
- Citations
- 30
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 13.63
Funders
- European Commission
- Deutsche Forschungsgemeinschaft
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg